Factor IX polypeptide mutant, its uses and method for its production
Disclosed are a modified FIX (factor IX) polypeptide comprising a leucine, cysteine, aspartic acid, glutamic acid, histidine, lysine, asparagine, glutamine or tyrosine in position 338; pharmaceutical preparations containing said modified FIX polypeptide; a nucleotide sequence coding for the modified FIX polypeptide; and a method for producing the modified FIX polypeptide.
1. An adeno-associated virus vector comprising:
a. a nucleic acid encoding a modified FIX polypeptide, the modified FIX polypeptide comprising at least 70% identity to SEQ ID NO: 2 and a leucine in position 338 of SEQ ID NO: 2; and
b. promoter sequences, transcription termination, and control elements.
2. A pharmaceutical composition comprising the adeno-associated virus vector of claim 1 .
3. The adeno-associated virus vector of claim 1 , wherein the nucleic acid encodes a modified FIX polypeptide identical to SEQ ID NO: 2 except for the leucine at position 338.
4. The adeno-associated virus vector of claim 1 , wherein the nucleic acid encodes for a FIX polypeptide precursor comprising at least 70% identity to SEQ ID NO: 1, said FIX polypeptide precursor comprising the modified FIX polypeptide.
5. The adeno-associated virus vector of claim 1 , wherein the nucleic acid comprises an overall sequence having at least 70% homology with the overall sequence of exon regions in the sequence having accession number K02402 (GenBank).
6. The adeno-associated virus vector of claim 1 , wherein the modified FIX polypeptide is an FIX variant, a chimeric FIX or a natural polymorphic variant.